Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor degrader (SERD) to a 30% reduction in the risk of invasive disease ...

People with epilepsy are at risk for hypertension, atrial fibrillation, and hyperlipidemia; they also have an elevated risk ...

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ) has issued an announcement. EBR Systems, Inc. has announced the expansion ...

Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in ...

In this dvm360 interview, Alex Sigmund, DVM, DACVO, shares practical tips for assessing ocular changes in senior pets, ...